TH - Will This Dual-Listed Bio-Pharma Catch New Year Action?

2024-01-02 10:47:47 ET

This %Pharmaceutical company is addressing the medical needs of patients with HIV and may be starting the new year off right. %Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced in a press release today the filing of a supplemental Biologics License Application for an intramuscular method of administration for the maintenance dose of Trogarzo ® (ibalizumab-uiyk) to the United States Food and Drug Administration for review.

The drug is offered in the United States in combination with other antiretrovirals and is indicated for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current ARV regimen. The firm offers its product under the brand name EGRIFTA, an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

AboutAllPennyStocks.com Media Inc.:

AllPennyStocks.com Media, Inc., founded in 1999, is one of North America’s largest and most comprehensive small-cap / penny stock financial portals.